Latest news

• Biogen grows in Q2, but Spinraza performance a concern

  Company banking on pipeline readouts and Tecfidra defence. Biogen has exceeded expectations in overall Q2 revenues from its multiple sclerosis franchise and biosimilars, but worse than expected performance from its key

• Biogen trumpets safety data for Tecfidera follow-up

  Much riding on blockbuster's successor

• Spinraza keeps Biogen afloat as Tecfidra stalls

  While this pipeline will take time to mature, and Tecfidra facing a patent challenge in the US, the strong performance of Spinraza and its biosimilar franchise helped Biogen keep moving forward. ... Biogen and partner Alkermes are also awaiting an FDA

• Biogen files Tecfidera follow-up in the US

  Improved GI tolerability is major selling point